Carole Ho
Tracked across 2 events · 31 articles · First seen Jul 16, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Eli Lilly and Company announced on September 11, 2026 the successful completion of its acquisition of Atai Life Sciences, a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. AtaiBeckley's lead investigational program, BPL-003,…
Impact: Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, publicly commented on the strategic rationale of the acquisition and the potential of AtaiBeckley's neuroplastogens.
Sep 11, 2026 · 6 articles
Business
Impact: Carole Ho, Executive Vice President and President of Lilly Neuroscience, commented on the acquisition, emphasizing the need for effective treatments for treatment-resistant depression.
Jul 16, 2026 · 25 articles
ERGEN INTELLIGENCE
Track Carole Ho live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard